Pathophysiology Of Hypertension

Pathophysiology Of Hypertension

Hypertension, often known as high blood pressure, is a chronic medical condition defined by elevated systemic arterial pressure. Its etiology is commonly associated with increased peripheral resistance in blood vessels, which is usually caused by constricted arterioles and increased arterial wall stiffness (Harrison et al., 2021). Genetics, obesity, high sodium consumption, and hormone imbalances are all factors. Because of the increased resistance, the heart has to work harder, resulting in left ventricular hypertrophy and the potential of heart and blood vessel damage (Nwabuo & Vasan, 2020). Furthermore, hypertension can harm essential organs such as the kidneys, brain, and eyes, making it a major risk factor for cardiovascular disease, stroke, and renal dysfunction. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, alleviates this persistent medical issue by relaxing blood vessels and decreasing blood pressure.

Patient Assessment Information

Before providing Lisinopril to a hypertensive patient, some important patient assessment parameters must be considered. One of the most important aspects of patient assessment is gathering blood pressure data from both the present and the past to build a baseline (Harrison et al., 2021). It is also critical to gather a thorough medical history from the patient. Any previous cardiovascular conditions the patient may have had, as well as any current medications, should be revealed.

To ensure the safe prescription of Lisinopril, it is also necessary to inquire about the patient's potential pharmacological allergies or intolerances (Nwabuo & Vasan, 2020).  In addition, an examination of the patient's current medicines and dietary supplements is required to identify any potential Lisinopril drug interactions or contraindications (NCBI, 2023). Finally, lifestyle factors are important in hypertension therapy (Vladimirovna et al., 2023). Inquiring about the patient's diet, exercise routine, and smoking habits can assist healthcare practitioners in developing a comprehensive therapy that includes lifestyle changes to augment medication intervention.

Pharmacodynamics And Pharmacokinetics of Lisinopril

 Lisinopril is an ACE inhibitor used to treat hypertension and cardiovascular disorders. The angiotensin-converting enzyme (ACE), which results in vasodilation, a reduction in cardiac afterload, and the suppression of aldosterone, is stopped from working (Rashid et al., 2020). This lowers blood pressure, lessens the strain on the heart, and has renal and cardioprotective effects. The effects of lisinopril start within hours, reach their peak in 6–8 hours, and can last up to 24 hours. Individual responses differ, requiring dose modifications. Caution is advised when discontinuing to prevent rebound hypertension. Due to possible negative effects and drug interactions, it should be used under medical professionals' supervision.

Lisinopril has a relatively extended duration of action and good oral absorption in terms of pharmacokinetics, allowing for once-daily dosing. It has a half-life of roughly 12 hours and reaches peak plasma concentrations in 6 hours (Baekdal et al., 2019). The principal route of elimination is renal excretion, and dosage modifications are critical in individuals with reduced renal function to prevent drug buildup (Rashid et al., 2020). Understanding these pharmacodynamic and pharmacokinetic features is critical for improving Lisinopril's efficacy in the treatment of hypertension and related heart conditions.

Biological Variance on Therapeutic Drug Monitoring

When considering the drug Lisinopril, biological variance plays a significant role in therapeutic drug monitoring. Age-related changes in renal function can influence drug clearance of Lisinopril. To avoid drug accumulation and associated negative effects, older adults may require dose changes (Rashid et al., 2020). On the other hand, genetic differences in drug metabolism enzymes may impact how efficiently Lisinopril is metabolized in the body. Pharmacogenetic testing can assist in identifying these variations and directing individualized dosing regimens (NCBI, 2023). Moreover, preexisting cardiovascular pathologies may influence Lisinopril responsiveness. For better blood pressure control, patients with heart failure or severe hypertension may require greater doses. Circadian rhythm and time of day can influence blood pressure fluctuations, affecting the timing of Lisinopril administration for optimal efficacy (Rhoads et al., 2020).

 Also, gender-specific changes in hormones and body composition can affect how drugs are absorbed and eliminated. For instance, women have a higher percentage of body fat than males. Since Lisinopril is a hydrophilic compound that primarily distributes in lean body mass, women may exhibit a different drug distribution profile (Baekdal et al., 2019). Furthermore, hormonal differences, such as estrogen levels in women, may impact medication metabolism and renal function (Moyer et al., 2019).

Patient Factors to Consider

One of the crucial patient factors is renal function. This function needs evaluation since Lisinopril is eliminated via the kidneys, and impaired renal function may affect its clearance (NCBI, 2023). Another factor can be confirming the absence of allergies to Lisinopril or other ACE inhibitors so as to prevent adverse reactions.  A review of concomitant medications is also essential to identify the potential drug interactions. Lastly, pregnancy or plans to become pregnant should be discussed, as Lisinopril is contraindicated during pregnancy due to potential harm to the developing fetus.

Benefits of Lisinopril

Lisinopril offers unique benefits over other drugs within the broad category of antihypertensive medications, including ACE inhibitors or angiotensin receptor blockers (ARBs) such as losartan and enalapril (Chen et al., 2021). One primary benefit is its well-established efficacy while reducing blood pressure along with preventing cardiovascular events. Furthermore, its once-daily dosing regimen fosters patient adherence and convenience, reducing the likelihood of missed doses (Bakhle, 2020).

 Beyond its blood pressure-lowering effects, Lisinopril has exhibited additional advantages, notably in its cardioprotective properties (Baekdal et al., 2019). It not only lowers the risk of cardiovascular events, like strokes and heart attacks, but it also helps to preserve kidney function, which is critical for individuals with hypertension-related renal issues (NCBI, 2023). In addition, the affordability and generic availability of Lisinopril make it a cost-effective choice for managing hypertension (Bakhle, 2020). This accessibility enhances its appeal, ensuring that a wider range of patients can benefit from its therapeutic effects.

Impact of Cardiac Disease on Prescribing and Monitoring

Patients with cardiac diseases, such as congestive heart failure often possess other comorbidities like diabetes or renal issues (Kemps et al., 2019). Cardiac patients may be consuming multiple medications, which increases the risk of polypharmacy-related complications (Chen et al., 2021).  Medication recommendations especially those for these other chronic comorbidities, may interact with cardiac medications or exacerbate heart problems (Malki et al., 2020). When prescribing drugs, healthcare professionals must thoroughly assess the patient's cardiac condition, renal health, and electrolyte levels and take into account any drug interactions (Harrison et al., 2021). In addition, cardiac disease often necessitates a personalized approach to prescribing. Patients with heart problems may require particular drugs, such as beta-blockers or ACE inhibitors, to adequately treat their disease (Strauss et al., 2021).

Based on cardiac function and treatment response, the dosage must be modified to meet the individual demands of the patient (Malki et al., 2020). The healthcare professionals must also evaluate the patient's overall risk profile, taking into account the patient's age, family history, and lifestyle choices (Vladimirovna, 2023). These elements have an impact on monitoring schedules and medication selections. To evaluate the medication's efficacy and swiftly identify any side effects, regular monitoring by medical specialists is required, including blood pressure checks and ECGs (Nwabuo & Vasan, 2020).

References

Bækdal, T. A., Borregaard, J., Hansen, C. W., Thomsen, M., & Anderson, T. W. (2019). Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clinical Pharmacokinetics, 58, 1193-1203. https://doi.org/10.1007/s40262-019-00756-2

Bakhle, Y. S. (2020). How ACE inhibitors transformed the renin–angiotensin system. British journal of pharmacology, 177(12), 2657-2665. https://doi.org/10.1111/bph.15045

Chen, R., Suchard, M. A., Krumholz, H. M., Schuemie, M. J., Shea, S., Duke, J., ... & Hripcsak, G. (2021). Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension, 78(3), 591-603. https://doi.org/10.1161/HYPERTENSIONAHA.120.16667

Hansen, D., Niebauer, J., Cornelissen, V., Barna, O., Neunhäuserer, D., Stettler, C., ... & Dendale, P. (2018). Exercise prescription in patients with different combinations of cardiovascular disease risk factors: a consensus statement from the EXPERT working group. Sports Medicine, 48, 1781-1797. https://doi.org/10.1007/s40279-018-0930-4

Harrison, D. G., Coffman, T. M., & Wilcox, C. S. (2021). Pathophysiology of hypertension: the mosaic theory and beyond. Circulation Research, 128(7), 847-863. https://doi.org/10.1161/CIRCRESAHA.121.318082

Kemps, H., Kränkel, N., Dörr, M., Moholdt, T., Wilhelm, M., Paneni, F., ... & Guazzi, M. (2019). Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). European Journal Of Preventive Cardiology, 26(7), 709-727. https://doi.org/10.1177/2047487318820420

Malki, M. A., & Pearson, E. R. (2020). Drug–drug–gene interactions and adverse drug reactions. The Pharmacogenomics Journal, 20(3), 355-366. https://doi.org/10.1038/s41397-019-0122-0

Moyer, A. M., Matey, E. T., & Miller, V. M. (2019). Individualized medicine: sex, hormones, genetics, and adverse drug reactions. Pharmacology Research & Perspectives, 7(6), e00541. https://doi.org/10.1002/prp2.541

National Center for Biotechnology Information (NCBI), (2023). Lisinopril. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482230/

Nwabuo, C. C., & Vasan, R. S. (2020). Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy. Current Hypertension Reports, 22, 1-18. https://doi.org/10.1007/s11906-020-1017-9

Rashid, M., Sarfraz, M., Arafat, M., Hussain, A., Abbas, N., Sadiq, M. W., ... & Bukhari, N. I. (2020). Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model. BMC Pharmacology and Toxicology, 21, 1-14.https://doi.org/10.1186/s40360-020-00429-y

Rhoads, M. K., Balagee, V., & Thomas, S. J. (2020). Circadian regulation of blood pressure: Of mice and men. Current Hypertension Reports, 22, 1-9. https://doi.org/10.1007/s11906-020-01043-3

Strauss, M. H., Hall, A. S., & Narkiewicz, K. (2021). The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovascular Drugs and Therapy, 1-14. https://doi.org/10.1007/s10557-021-07248-1

Vladimirovna, S. V. (2023). Pathogenetic relationships of arterial hypertension and insulin resistance. IQRO, 2(1), 685-691. http://wordlyknowledge.uz/index.php/iqro/article/view/414/483

Looking For Complete Assignment Sample Get It On WhatsApp